Thiazole Compound Preparation for Targeted ER Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases and skin autoimmune diseases, such as vitiligo, psoriasis, and eczema, provide only symptomatic relief and have significant side effects, with a need for more targeted and effective treatments.
Innovation Solution
Development of N-[2-[2-(4-chlorophenyl)-4-thiazolyl]ethyl]-butanamide, which improves ER protein folding output and induces chaperone expression, preventing melanocyte death and restoring ER homeostasis, thereby treating autoimmune diseases and skin disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (steroids, phototherapy, topical treatments) are used for autoimmune diseases and skin disorders, then symptomatic relief is achieved, but side effects occur and targeted effectiveness is limited
Solution Approach 1:
The patent changes the molecular parameter of the treatment by introducing a specific ER stress modulator compound (N-[2-[2-(4-chlorophenyl)-4-thiazolyl]ethyl]-butanamide) that targets the endoplasmic reticulum stress pathway. This parameter change from non-specific symptomatic treatment to specific molecular pathway targeting resolves the contradiction by achieving reliable therapeutic effectiveness through ER homeostasis restoration while minimizing harmful side effects associated with conventional broad-spectrum therapies
Solution Approach 2:
The patent uses ER stress modulation as an intermediary mechanism between the external stimulus (compound administration) and the internal cellular response (melanocyte protection, immune regulation). The compound acts as a mediator that restores ER homeostasis, which in turn protects against autoimmune-mediated cell death and provides targeted therapeutic effect without the harmful side effects of conventional direct immunosuppression or steroid therapy
2Manufacturing precision
If existing therapies are used for skin autoimmune diseases, then some therapeutic benefit is obtained, but targeted therapy and precision are insufficient
Solution Approach 1:
The patent applies local quality by targeting the endoplasmic reticulum stress pathway specifically in melanocytes and immune cells involved in skin autoimmune diseases. The compound N-[2-[2-(4-chlorophenyl)-4-thiazolyl]ethyl]-butanamide provides localized therapeutic action at the molecular level within affected cells, rather than systemically suppressing the immune system. This localized molecular targeting achieves high therapeutic precision while maintaining adaptability across different skin autoimmune conditions through a common ER stress mechanism
Solution Approach 2:
The patent demonstrates universality by showing that the ER stress modulator compound can treat multiple different skin autoimmune diseases (vitiligo, psoriasis, eczema, lichen planus) through a common mechanism of restoring ER homeostasis and preventing autoimmune-mediated cell death. This multi-functional approach provides targeted therapy across diverse disease presentations, resolving the contradiction between precision and versatility
Data Source
AI summary
The present invention relates to a process for preparing N-[2-[2-(4-chlorophenyl)-4-thiazolyl]ethyl]-butanamide. The present invention further relates to a pharmaceutical formulation and the use of said pharmaceutical formulation consisting of N-[2-[2-(4-chlorophenyl)-4-thiazolyl]ethyl]-butanamide or pharmaceutically acceptable salts thereof as active compound for the treatment and prevention of autoimmune diseases and diseases involving skin immunology, skin autoimmune diseases and pigmentation disorders.